Journal of Affective Disorders
January 5, 2024
Kwonmok Ko, Emma I Kopra, Anthony J. Cleare et al.
1 citation
correction
The authors wish to express their regret regarding an error in the publication of the original article. In Table 3, titled “Psilocybin studies on depressive disorders,” specifically in the fourth row related to the study conducted by Carhart-Harris et al. (2016), the main results column inaccurately presented the Cohen's d figure, which included data from Carhart-Harris et al. (2018) that...
Journal of Affective Disorders
February 1, 2023
Kwonmok Ko, Emma I Kopra, Anthony J. Cleare et al.
144 citations
Psychedelic therapy shows promise for Major Depressive Disorder, especially when treatment-resistant, as well as life-threatening illness distress. The objective of this systematic review, inclusive of meta-analysis, is to examine recent clinical research on the therapeutic effects of classic psychedelics on depressive symptoms. Fourteen psychedelic therapy studies, utilising psilocybin,...
Neuropsychiatric Disease and Treatment
2023
Kwonmok Ko, Ben Carter, Anthony J. Cleare et al.
26 citations
In psychedelic therapy, mystical as well as challenging experience may influence therapeutic outcome. However, predictors of such experience have not been sufficiently established. Determining predictors of their intensity is, therefore, potentially beneficial in targeting psilocybin therapy for depression. In a post hoc data analysis of a Phase 1, randomised, double-blind, placebo-controlled,...
Frontiers in Psychiatry
July 12, 2022
Kwonmok Ko, Gemma Knight, James Rucker et al.
296 citations
The mystical experience is a potential psychological mechanism to influence outcome in psychedelic therapy. It includes features such as oceanic boundlessness, ego dissolution, and universal interconnectedness, which have been closely linked to both symptom reduction and improved quality of life. In this review, 12 studies of psychedelic therapy utilizing psilocybin, ayahuasca, or ketamine were...